Contemporary Immunosuppression in Simultaneous Heart–Kidney Transplantation: A United Network for Organ‐Sharing Database Analysis

Xinyi Huang; William L. Baker; Paolo C. Colombo; Melana Yuzefpolskaya; Douglas L. Jennings

doi:10.1002/phar.70144

April 8, 2026Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

Contemporary Immunosuppression in Simultaneous Heart–Kidney Transplantation: A United Network for Organ‐Sharing Database Analysis

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the outcomes of different immunosuppression induction strategies in simultaneous heart-kidney transplant (SHKT) recipients.
Data analysis from the United Network for Organ Sharing (UNOS) database.
Comparison of 1-year outcomes across various induction strategies.
Specific focus on patients receiving basiliximab.
1-year outcomes are similar across different induction strategies in SHKT recipients.
Basiliximab is effective for standard-risk SHKT recipients.

Implication

Database analysis reveals similar outcomes for induction strategies in heart-kidney transplant recipients, suggesting effectiveness of basiliximab.

Abstract

Contemporary SHKT recipients experience similar 1-year outcomes across induction strategies. Basiliximab may be sufficient for standard-risk SHKT recipients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/69d8958f6c1944d70ce069bb https://doi.org/10.1002/phar.70144

View Full Paper

Ask AI

Bookmark

Share

Contemporary Immunosuppression in Simultaneous Heart–Kidney Transplantation: A United Network for Organ‐Sharing Database Analysis

Key Points

Implication

Abstract

Discussion

Cite This Study

Contemporary Immunosuppression in Simultaneous Heart–Kidney Transplantation: A United Network for Organ‐Sharing Database Analysis

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading